These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8398322)

  • 21. Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil.
    Levitt M; Warr D; Yelle L; Rayner HL; Lofters WS; Perrault DJ; Wilson KS; Latreille J; Potvin M; Warner E
    N Engl J Med; 1993 Apr; 328(15):1081-4. PubMed ID: 8455665
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Granisetron. A pharmacoeconomic evaluation of its use in the prophylaxis of chemotherapy-induced nausea and vomiting.
    Plosker GL; Benfield P
    Pharmacoeconomics; 1996 Apr; 9(4):357-74. PubMed ID: 10160110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-efficacy analysis of ondansetron regimens for control of emesis induced by noncisplatin, moderately emetogenic chemotherapy.
    Lachaine J; Laurier C
    Am J Health Syst Pharm; 2002 Oct; 59(19):1837-46. PubMed ID: 12374068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Global experience with ondansetron and future potential.
    Butcher ME
    Oncology; 1993; 50(3):191-7. PubMed ID: 8459991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progress in the control of acute and delayed emesis induced by cisplatin.
    Gandara DR
    Eur J Cancer; 1991; 27 Suppl 1():S9-11; discussion S22. PubMed ID: 1831633
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tropisetron, ondansetron, and granisetron for control of chemotherapy-induced emesis in Turkish cancer patients: a comparison of efficacy, side-effect profile, and cost.
    Abali H; Celik I
    Cancer Invest; 2007; 25(3):135-9. PubMed ID: 17530482
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Italian Group For Antiemetic Research.
    Lancet; 1992 Jul; 340(8811):96-9. PubMed ID: 1352024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy.
    Sledge GW; Einhorn L; Nagy C; House K
    Cancer; 1992 Nov; 70(10):2524-8. PubMed ID: 1423181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effectiveness and cost of 5-HT3-antagonists in acute chemotherapy-induced emesis. Health-economic analysis based on current meta-analytic data].
    Brüggenjürgen B; du Bois A
    Med Klin (Munich); 1997 Dec; 92(12):747-52. PubMed ID: 9483920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Difference in persistence of efficacy of two antiemetic regimens on acute emesis during cisplatin chemotherapy. The Italian Group for Antiemetic Research.
    J Clin Oncol; 1993 Dec; 11(12):2396-404. PubMed ID: 8246029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative evaluation of the clinical efficacy and safety of ondansetron and metoclopramide in the prophylaxis of emesis induced by cancer chemotherapy regimens including cisplatin.
    Advani SH; Gopal R; Dhar AK; Lal HM; Cooverji ND
    J Assoc Physicians India; 1996 Feb; 44(2):127-30. PubMed ID: 10999066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The combination of metoclopramide, methylprednisolone and ondansetron against antiblastic-delayed emesis: a randomised phase II study.
    Mustacchi G; Ceccherini R; Leita ML; Sandri P; Milani S; Carbonara T
    Anticancer Res; 1997; 17(2B):1345-8. PubMed ID: 9137496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. International Emesis Study Group.
    Kaasa S; Kvaløy S; Dicato MA; Ries F; Huys JV; Royer E; Carruthers L
    Eur J Cancer; 1990 Mar; 26(3):311-4. PubMed ID: 2141487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting.
    Markham A; Sorkin EM
    Drugs; 1993 Jun; 45(6):931-952. PubMed ID: 7691500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness analysis of antiemetic treatment.
    Bleiberg H; Autier P; Michaux D
    Support Care Cancer; 1994 May; 2(3):145-9. PubMed ID: 8032699
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical studies of oral antiemetic drugs on delayed emesis induced by cancer chemotherapy].
    Sawaguchi K; Yabushita H; Tsukada H; Yamada H; Noguchi M; Nakanishi M
    Gan To Kagaku Ryoho; 1999 Jan; 26(1):117-23. PubMed ID: 9987507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ondansetron: a review of its use as an antiemetic in children.
    Culy CR; Bhana N; Plosker GL
    Paediatr Drugs; 2001; 3(6):441-79. PubMed ID: 11437189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness analysis of granisetron-based versus standard antiemetic regimens in low-emetogenic chemotherapy: a hospital-based perspective from Malaysia.
    Keat CH; Ghani NA
    Asian Pac J Cancer Prev; 2013; 14(12):7701-6. PubMed ID: 24460356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-emetic control with ondansetron in the chemotherapy of breast cancer: a review.
    Marschner N
    Eur J Cancer; 1991; 27 Suppl 1():S15-7; discussion S22. PubMed ID: 1831629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.